102 related articles for article (PubMed ID: 9559305)
1. [Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day].
Bourdeaux R; Pannetier P; Younos C; Desor D; Lehr PR; Capolaghi B
Encephale; 1998; 24(1):57-61. PubMed ID: 9559305
[TBL] [Abstract][Full Text] [Related]
2. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
Maes M; Westenberg H; Vandoolaeghe E; Demedts P; Wauters A; Neels H; Meltzer HY
J Clin Psychopharmacol; 1997 Oct; 17(5):358-64. PubMed ID: 9315986
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine in depressed patients on dialysis.
Blumenfield M; Levy NB; Spinowitz B; Charytan C; Beasley CM; Dubey AK; Solomon RJ; Todd R; Goodman A; Bergstrom RF
Int J Psychiatry Med; 1997; 27(1):71-80. PubMed ID: 9565715
[TBL] [Abstract][Full Text] [Related]
4. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
[TBL] [Abstract][Full Text] [Related]
5. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study.
Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Michelson D; Hornig-Rohan M; Beasley CM
Am J Psychiatry; 1997 Jul; 154(7):963-9. PubMed ID: 9210747
[TBL] [Abstract][Full Text] [Related]
6. Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine.
Piwowarska J; Dryll K; Szelenberger W; Pachecka J
Acta Pol Pharm; 2008; 65(1):159-64. PubMed ID: 18536191
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine once every third day in the treatment of major depressive disorder.
Tural U; Onder E
Eur Arch Psychiatry Clin Neurosci; 2003 Dec; 253(6):307-12. PubMed ID: 14714120
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function.
Levy NB; Blumenfield M; Beasley CM; Dubey AK; Solomon RJ; Todd R; Goodman A; Bergstrom RR
Gen Hosp Psychiatry; 1996 Jan; 18(1):8-13. PubMed ID: 8666216
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
Brunswick DJ; Amsterdam JD; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Beasley CM
J Affect Disord; 2002 Apr; 68(2-3):243-9. PubMed ID: 12063152
[TBL] [Abstract][Full Text] [Related]
10. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
Joyce PR; Mulder RT; Luty SE; McKenzie JM; Miller AL; Rogers GR; Kennedy MA
Int J Neuropsychopharmacol; 2003 Dec; 6(4):339-46. PubMed ID: 14604448
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression.
Amsterdam JD; Luo L; Shults J
J Clin Psychopharmacol; 2013 Jun; 33(3):420-4. PubMed ID: 23609385
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; Galil N; Kaplan S; Busner J; Nilsson ME; Brown EB; Jacobson JG
J Child Adolesc Psychopharmacol; 2006; 16(1-2):207-17. PubMed ID: 16553541
[TBL] [Abstract][Full Text] [Related]
13. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
Papakostas GI; Petersen T; Lebowitz BD; Mischoulon D; Ryan JL; Nierenberg AA; Bottiglieri T; Alpert JE; Rosenbaum JF; Fava M
Int J Neuropsychopharmacol; 2005 Dec; 8(4):523-8. PubMed ID: 15877935
[TBL] [Abstract][Full Text] [Related]
14. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
Sit D; Perel JM; Luther JF; Wisniewski SR; Helsel JC; Wisner KL
J Clin Psychopharmacol; 2010 Aug; 30(4):381-6. PubMed ID: 20631556
[TBL] [Abstract][Full Text] [Related]
15. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
Amsterdam JD; Shults J
J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
[TBL] [Abstract][Full Text] [Related]
16. Serum cortisol concentration in patients with major depression after treatment with fluoxetine.
Piwowarska J; Chimiak A; Matsumoto H; Dziklińska A; Radziwoń-Zaleska M; Szelenberger W; Pachecka J
Psychiatry Res; 2012 Aug; 198(3):407-11. PubMed ID: 22429479
[TBL] [Abstract][Full Text] [Related]
17. Personality traits and recovery from major depressive disorder.
Kronström K; Salminen JK; Hietala J; Kajander J; Vahlberg T; Markkula J; Rasi-Hakala H; Karlsson H
Nord J Psychiatry; 2011 Feb; 65(1):52-7. PubMed ID: 20500120
[TBL] [Abstract][Full Text] [Related]
18. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
Kim J; Riggs KW; Misri S; Kent N; Oberlander TF; Grunau RE; Fitzgerald C; Rurak DW
Br J Clin Pharmacol; 2006 Feb; 61(2):155-63. PubMed ID: 16433870
[TBL] [Abstract][Full Text] [Related]
20. Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Başterzi AD; Yazici K; Buturak V; Cimen B; Yazici A; Eskandari G; Tot Acar S; Taşdelen B
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):70-5. PubMed ID: 19804808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
